ES2721098T3 - Compound chromatography compounds - Google Patents
Compound chromatography compounds Download PDFInfo
- Publication number
- ES2721098T3 ES2721098T3 ES14786355T ES14786355T ES2721098T3 ES 2721098 T3 ES2721098 T3 ES 2721098T3 ES 14786355 T ES14786355 T ES 14786355T ES 14786355 T ES14786355 T ES 14786355T ES 2721098 T3 ES2721098 T3 ES 2721098T3
- Authority
- ES
- Spain
- Prior art keywords
- substituted
- unsubstituted
- alkenyl
- alkyl
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D411/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
Un compuesto de fórmula Ib como se muestra a continuación,**Fórmula** en la que R1 es H, -CI, -F, -Br, -I, -OH, -CN, -NO2, alquilo C1-C6 sustituido o sin sustituir, alquenilo C1-C6 sustituido o sin sustituir, cicloalquilo, arilo o heteroarilo sustituido o sin sustituir; R3 es -[(CH2)2E]n(CH2)2NR'R" y n es cualquier número entero de 0 a 30, en la que R' y R" son cada uno independientemente H, alquilo C1-C6 sustituido o sin sustituir, alquenilo C1-C6 sustituido o sin sustituir o cicloalquilo sustituido o sin sustituir y E es CH2, O, NH o S, o E está ausente; R4 es H, -Cl, -F, -Br, -I, -OH, -CN, -NO2, alquilo C1-C6 sustituido o sin sustituir, alquenilo C1-C6 sustituido o sin sustituir, cicloalquilo, arilo o heteroarilo sustituido o sin sustituir; Y1 e Y3 son independientemente C, O, N, NR2 o S, en la que R2 es H, alquilo C1-C6 sustituido o sin sustituir, alquenilo C1-C6 sustituido o sin sustituir, cicloalquilo, arilo o heteroarilo sustituido o sin sustituir; e Y2 es C o N; o a una sal del mismo.A compound of formula Ib as shown below, ** Formula ** wherein R1 is H, -CI, -F, -Br, -I, -OH, -CN, -NO2, substituted C1-C6 alkyl or unsubstituted, substituted or unsubstituted C1-C6 alkenyl, substituted or unsubstituted cycloalkyl, aryl, or heteroaryl; R3 is - [(CH2) 2E] n (CH2) 2NR'R "and n is any integer from 0 to 30, where R 'and R" are each independently H, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkenyl or substituted or unsubstituted cycloalkyl and E is CH2, O, NH or S, or E is absent; R4 is H, -Cl, -F, -Br, -I, -OH, -CN, -NO2, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkenyl, substituted cycloalkyl, aryl or heteroaryl or unsubstituted; Y1 and Y3 are independently C, O, N, NR2, or S, wherein R2 is H, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkenyl, substituted or unsubstituted cycloalkyl, aryl, or heteroaryl; and Y2 is C or N; or a salt of it.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361885146P | 2013-10-01 | 2013-10-01 | |
US201462025994P | 2014-07-17 | 2014-07-17 | |
PCT/IB2014/064998 WO2015049651A1 (en) | 2013-10-01 | 2014-10-01 | Compounds for affinity chromatography and for extending the half-life of a therapeutic agent |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2721098T3 true ES2721098T3 (en) | 2019-07-26 |
Family
ID=51743521
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES14786355T Active ES2721098T3 (en) | 2013-10-01 | 2014-10-01 | Compound chromatography compounds |
Country Status (12)
Country | Link |
---|---|
US (2) | US9809558B2 (en) |
EP (1) | EP3052483B1 (en) |
JP (1) | JP2016534984A (en) |
KR (1) | KR20160060660A (en) |
CN (1) | CN105593222B (en) |
AU (1) | AU2014330781B2 (en) |
BR (1) | BR112016007371A2 (en) |
CA (1) | CA2925862A1 (en) |
ES (1) | ES2721098T3 (en) |
RU (1) | RU2016117052A (en) |
SG (1) | SG11201601870VA (en) |
WO (1) | WO2015049651A1 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20170066839A1 (en) * | 2015-09-08 | 2017-03-09 | Merck Patent Gmbh | Novel affinity chromatography media for removal of anti-a and/or anti-b antibodies |
US10697983B2 (en) | 2015-09-08 | 2020-06-30 | Merck Patent Gmbh | Methods of evaluating quality of media suitable for removing anti-A or anti-B antibodies |
US10697982B2 (en) | 2015-09-08 | 2020-06-30 | Merck Patent Gmbh | Methods of evaluating quality of a chromatography media which binds anti-A or anti-B antibodies |
JPWO2018181738A1 (en) * | 2017-03-30 | 2020-02-13 | 日立化成株式会社 | Separation material |
US20220009959A1 (en) * | 2018-11-26 | 2022-01-13 | North Carolina State University | Peptide ligands for capture of host cell proteins |
MX2021007444A (en) | 2018-12-21 | 2021-08-05 | Jiangsu Hengrui Medicine Co | Bispecific protein. |
WO2021113627A1 (en) | 2019-12-06 | 2021-06-10 | Vertex Pharmaceuticals Incorporated | Substituted tetrahydrofurans as modulators of sodium channels |
US11827627B2 (en) | 2021-06-04 | 2023-11-28 | Vertex Pharmaceuticals Incorporated | N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels |
KR20240024935A (en) | 2021-06-18 | 2024-02-26 | 알리고스 테라퓨틱스 인코포레이티드 | Methods and compositions for targeting PD-L1 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH187973A4 (en) * | 1973-02-09 | 1977-03-31 | Hoechst Ag | Process for the optical brightening of textile materials |
US4722896A (en) | 1981-01-26 | 1988-02-02 | The Beth Israel Hospital Association | Method for affinity purification of hybridoma antibodies |
US5849874A (en) | 1991-07-12 | 1998-12-15 | Gist-Brocades, N.V. | Process for the purification of serum albumin |
JP2825755B2 (en) * | 1993-04-07 | 1998-11-18 | 大塚製薬株式会社 | Peripheral vasodilator containing piperidine derivative as active ingredient and novel piperidine derivative |
EP0802797A1 (en) * | 1994-02-03 | 1997-10-29 | The Picower Institute For Medical Research | Compositions and methods for advanced glycosylation endproduct-mediated modulation of amyloidosis |
GB9914825D0 (en) * | 1999-06-24 | 1999-08-25 | Smithkline Beecham Spa | Novel compounds |
CA2363274A1 (en) | 1999-12-27 | 2001-07-05 | Japan Tobacco Inc. | Fused-ring compounds and use thereof as drugs for hepatitis c |
DE10139416A1 (en) * | 2001-08-17 | 2003-03-06 | Aventis Pharma Gmbh | Aminoalkyl substituted aromatic bicycles, process for their preparation and their use as medicaments |
CA2481334A1 (en) | 2002-04-01 | 2003-10-16 | Anthony C. Stevens | Tissue-specific endothelial membrane proteins |
DE60326735D1 (en) * | 2002-08-02 | 2009-04-30 | Genesoft Pharmaceuticals Inc | BIARYL COMPOUNDS WITH ANTI-INFECTIVE EFFECT |
US7777051B2 (en) | 2003-05-13 | 2010-08-17 | Icagen, Inc. | Asymmetric benzimidazoles and related compounds as potassium channel modulators |
US8629147B2 (en) | 2005-11-03 | 2014-01-14 | Chembridge Corporation | Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders |
HUE052816T2 (en) | 2009-07-31 | 2021-05-28 | Ascendis Pharma As | Biodegradable polyethylene glycol based water-insoluble hydrogels |
WO2011048018A1 (en) * | 2009-10-19 | 2011-04-28 | Boehringer Ingelheim International Gmbh | Cyclopentanecarboxamide derivatives, medicaments containing such compounds and their use |
KR102008946B1 (en) * | 2010-08-03 | 2019-08-08 | 노브알리스 도이칠란트 게엠베하 | LIGANDS FOR ANTIBODY AND Fc-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMATOGRAPHY |
WO2012020080A2 (en) | 2010-08-12 | 2012-02-16 | Graffinity Pharmaceuticals Gmbh | LIGANDS FOR ANTIBODY AND Fc-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMATOGRAPHY II |
WO2012140647A2 (en) | 2011-04-11 | 2012-10-18 | Yeda Research And Development Co. Ltd | Albumin binding probes and drug conjugates thereof |
UA115576C2 (en) | 2012-12-06 | 2017-11-27 | Байєр Фарма Акцієнгезелльшафт | BENZIMIDASOL DERIVATIVES AS ER4 ANGAGONES |
EP2752426A1 (en) | 2013-01-03 | 2014-07-09 | Covagen AG | Human serum albumin binding compounds and fusion proteins thereof |
-
2014
- 2014-10-01 EP EP14786355.9A patent/EP3052483B1/en active Active
- 2014-10-01 ES ES14786355T patent/ES2721098T3/en active Active
- 2014-10-01 CN CN201480054551.4A patent/CN105593222B/en not_active Expired - Fee Related
- 2014-10-01 AU AU2014330781A patent/AU2014330781B2/en not_active Ceased
- 2014-10-01 BR BR112016007371A patent/BR112016007371A2/en not_active Application Discontinuation
- 2014-10-01 RU RU2016117052A patent/RU2016117052A/en not_active Application Discontinuation
- 2014-10-01 US US15/026,725 patent/US9809558B2/en active Active
- 2014-10-01 WO PCT/IB2014/064998 patent/WO2015049651A1/en active Application Filing
- 2014-10-01 CA CA2925862A patent/CA2925862A1/en not_active Abandoned
- 2014-10-01 JP JP2016519325A patent/JP2016534984A/en active Pending
- 2014-10-01 SG SG11201601870VA patent/SG11201601870VA/en unknown
- 2014-10-01 KR KR1020167008267A patent/KR20160060660A/en not_active Application Discontinuation
-
2017
- 2017-09-07 US US15/698,020 patent/US9938243B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US9938243B2 (en) | 2018-04-10 |
KR20160060660A (en) | 2016-05-30 |
RU2016117052A3 (en) | 2018-06-27 |
RU2016117052A (en) | 2017-11-10 |
WO2015049651A1 (en) | 2015-04-09 |
JP2016534984A (en) | 2016-11-10 |
BR112016007371A2 (en) | 2017-08-01 |
CA2925862A1 (en) | 2015-04-09 |
AU2014330781B2 (en) | 2017-05-04 |
SG11201601870VA (en) | 2016-04-28 |
US9809558B2 (en) | 2017-11-07 |
US20160221962A1 (en) | 2016-08-04 |
EP3052483B1 (en) | 2019-02-06 |
US20170369448A1 (en) | 2017-12-28 |
EP3052483A1 (en) | 2016-08-10 |
AU2014330781A1 (en) | 2016-04-07 |
CN105593222A (en) | 2016-05-18 |
CN105593222B (en) | 2018-02-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2721098T3 (en) | Compound chromatography compounds | |
EA201591703A1 (en) | SUBSTITUTED 2-ABABILITIES AND THEIR APPLICATION AS OREXIN RECEPTOR MODULATORS | |
CY1120188T1 (en) | NAPHYTHRIDINE PRODUCERS USEFUL AS INTEGRINE COMPONENTS avv6 | |
PE20160523A1 (en) | DERIVATIVES OF ARYL OR HETEROARYL AS INHIBITORS OF SMALL MOLECULES OF FIBROSIS | |
CO7400871A2 (en) | Heteroaryl substituted pyridyl compounds useful as kinase modulators | |
ECSP11010912A (en) | PIRROL COMPOUNDS | |
EA201590979A1 (en) | METHODS AND INTERMEDIATE CHEMICAL COMPOUNDS TO OBTAIN PHARMACEUTICAL MEANS | |
UA111626C2 (en) | DIGIDROCHINOLIN-2-ON DERIVATIVES | |
PE20151779A1 (en) | SUBSTITUTED XANTHINES AND METHODS OF USE OF THEM | |
EA201690019A1 (en) | AMINOTRIASIN DERIVATIVE AND CONTAINING ITS PHARMACEUTICAL COMPOSITION | |
AR093184A1 (en) | PIRIMIDINE COMPOSITE REPLACED AS AN INHIBITOR OF QUINURENINA-3-MONOOXIGENASA AND PHARMACEUTICAL COMPOSITION THAT UNDERSTAND IT | |
AR080057A1 (en) | PIRIDINES DISUSTITUTED AS ANTI-BANERIGENS | |
BR112013018732A2 (en) | new aryl benzocycloalkyl amide derivatives | |
CO2017001178A2 (en) | Derivative of pyridone having a tetrahydropyranyl methyl group | |
EA201691031A1 (en) | SYNTHESIS OF MACROCYCLIC TRIPEPTIDE INHIBITING HCV NS3 | |
EA201690879A1 (en) | NEW TRIAZOLOPIRIDINE CONNECTION | |
CY1117688T1 (en) | Tetrahydropyrrolothiazine compounds | |
PE20150598A1 (en) | N-PROP-2-INYL CARBOXAMIDE DERIVATIVES AND THEIR USE AS ANTAGONISTS OF THE POTENTIAL TRANSIENT RECEPTOR OF SUBFAMILY A, MEMBER 1 | |
RS53909B1 (en) | 5-(phenyl/pyridinyl-ethinyl)-2-pyridine/2-pyrimidine-carborxamides as mglur5 modulators | |
EA201391267A1 (en) | METHOD OF OBTAINING ORGANIC COMPOUNDS | |
CR20160082A (en) | NEW DERIVATIVE OF TRIAZINA | |
PE20141168A1 (en) | DERIVATIVES OF PYRAZOLIDIN-3-ONA | |
BR112013005823B8 (en) | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OR PREVENTION OF DISORDERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREFNEPHRINE OR DOPAMINE | |
SA519400868B1 (en) | Heteroaromatic modulators of the retinoid-related orphan receptor gamma | |
BR112013000253A2 (en) | (3-methylpyrrolidin-3-yl) methyl pyridinyl ether derivatives and their use as nk-3 receptor antagonists |